DECIPHERA PHARMACEUTICALS INC stock forecast: up to 8.38 USD DCPH stock price prognosis


Forecast for Fri 28 Jan 2022 price 22.72

DECIPHERA PHARMACEUTICALS INC stock price forecast for further price development up to 4.72% (time horizon: 1 day) and price target of 8.38 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) DECIPHERA PHARMACEUTICALS INC share price prediction for 2022-01-28 with daily closed price projections

Key Facts

Symbol DCPH 

ISIN US24344T1016 

CUSIP 24344T101

Currency USD

Category Pharmaceutical Preparations

Forecast price change %

News sentiment (0.62)

Finance numbers

Revenue 67,181,000.0

Earnings per share -4.48

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.

Summerized Form 10-K with GPT-2

We have one approved drug, QINLOCK, which was developed through our proprietary platform. The study is being conducted at 122 investigational sites in 22 countries. We also announced plans to file a U.K. MAA for QINLOCK in fourth-line GIST. We successfully completed enrollment of 453 patients in INTRIGUE. GIST can occur at any age, but is more common in individuals aged over 50 years. However, regorafenib does not inhibit all KIT mutations in exon 17 or 18. Cambridge, MA: Blueprint Medicines Corp; 2020; (10) Lopes LF, Bacchi CE. Vimseltinib was generally well-tolerated in patients with TGCT not amenable to surgery. No SAEs related to vimseltinib were reported in the TGCT patients. The following figure depicts the results of these assays. Median treatment duration for the mITT population was 4.2 months. Rebastinib in combination with carboplatin was generally well-tolerated. Drugs are also subject to other federal, state, and local statutes and regulations. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials. In this event, the application must be resubmitted with the additional information. FDA review of an initial PMA may require several years to complete. This has led to significant variations in the Member State regimes. This is currently expected to occur in December 2021. There is no certainty that an adequacy decision will be granted. Unlike Medicare Parts A and B, Part D coverage is not standardized. This final rule codified the CMS\'s policy change that was effective January 1, 2019. The market implications of the final rule and guidance are unknown at this time. Moreover, data subjects can claim damages resulting from infringement of the GPDR. ITEM 1A. RISK FACTORSOur business is subject to numerous material and other risks. We may face other limitations or issues related to the price of QINLOCK. As a result, increasingly high barriers are being erected to the entry of new products. In March 2010, the ACA was enacted into law. We generally contract with third parties for the disposal of these materials and wastes. We currently have no products that are approved for sale with the exception of QINLOCK. Three of our drug candidates are only in Phase 1 or Phase 1/2 studies. It is unknown how long these disruptions could continue, were they to occur. We commenced operations in 2003. Adequate additional funds may not be available to us on acceptable terms, or at all. As a general matter, our manufacturers represent our sole source of supply.

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 44.53/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.
    • Stock price is under book price value.

Institutional ownership list is based on filling form information

Holding name Date Amount
Edmonds Duncan Registered Investment Advisors, LLC 2021-06-30 17747
Meridian Wealth Partners, LLC 2021-03-31 14
ORBIMED ADVISORS LLC 2021-03-31 1380900

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Commonwealth Trust 2021-05-31 17319 Long
Fidelity Concord Street Trust 2021-05-31 69594 Long
SPARROW FUNDS 2021-05-31 1010 Long
Fidelity Salem Street Trust 2021-04-30 288487 Long


CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1494875 Taylor Michael Douglas 2021-05-03 SALE Accept Accept Accept Accept
1713712 Flynn Daniel Lee 2021-02-16 SALE Accept Accept Accept Accept
1715153 Bristol James Arthur 2021-04-12 SALE Accept Accept Accept Accept
1325710 Sherman Matthew L 2021-10-04 SALE Reject Accept Accept Accept

DECIPHERA PHARMACEUTICALS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

On-Balance Volume information for DECIPHERA PHARMACEUTICALS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for DECIPHERA PHARMACEUTICALS INC. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for DECIPHERA PHARMACEUTICALS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for DECIPHERA PHARMACEUTICALS INC. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for DECIPHERA PHARMACEUTICALS INC. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for DECIPHERA PHARMACEUTICALS INC. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for DECIPHERA PHARMACEUTICALS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2021-12-06 8.38 2021-12-04 08:17
2021-12-07 8.83 2021-12-04 08:17
2021-12-10 9.94 2021-12-04 08:17
2021-12-13 10.35 2021-12-04 08:17
2021-12-14 10.75 2021-12-04 08:17
2021-12-20 12.27 2021-12-04 08:17
2021-12-21 12.71 2021-12-04 08:17
2021-12-27 14.18 2021-12-04 08:17
2021-12-28 14.60 2021-12-04 08:17
2021-12-29 15.04 2021-12-04 08:17
2021-12-30 15.44 2021-12-04 08:17
2021-12-08 9.24 2021-12-04 08:17
2021-12-09 9.58 2021-12-04 08:17
2021-12-15 11.20 2021-12-04 08:17
2021-12-16 11.55 2021-12-04 08:17
2021-12-17 11.91 2021-12-04 08:17
2021-12-31 15.82 2021-12-04 08:17
2022-01-14 19.48 2021-12-04 08:17
2021-12-22 13.08 2021-12-04 08:17
2021-12-23 13.46 2021-12-04 08:17
2021-12-24 13.75 2021-12-04 08:17
2022-01-03 16.21 2021-12-04 08:17
2022-01-04 16.60 2021-12-04 08:17
2022-01-05 16.99 2021-12-04 08:17
2022-01-06 17.36 2021-12-04 08:17
2022-01-07 17.72 2021-12-04 08:17
2022-01-10 18.08 2021-12-04 08:17
2022-01-11 18.44 2021-12-04 08:17
2022-01-12 18.80 2021-12-04 08:17
2022-01-13 19.14 2021-12-04 08:17
2022-01-17 19.82 2021-12-04 08:17
2022-01-20 20.84 2021-12-04 08:17
2022-01-21 21.16 2021-12-04 08:17
2022-01-24 21.48 2021-12-04 08:17
2022-01-25 21.79 2021-12-04 08:17
2022-01-18 20.16 2021-12-04 08:17
2022-01-19 20.51 2021-12-04 08:17
2022-01-26 22.11 2021-12-04 08:17
2022-01-27 22.42 2021-12-04 08:17
2022-01-28 22.72 2021-12-04 08:17